

Laurus Labs Limited  
Corporate Office  
2<sup>nd</sup> Floor, Serene Chambers, Road No. 7  
Banjara Hills, Hyderabad - 500034, Telangana, India  
T +91 40 39804333 / 2342 0500 / 501  
F +91 40 3980 4320



July 12, 2019

To  The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> Floor, Dalal Street Mumbai – 400001  <b>Code: 540222</b>	To  The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051  <b>Code: LAURUSLABS</b>
--	---

Dear Sirs,

**Sub: Laurus Labs completed the USFDA inspection of Unit 4 at Visakhapatnam**

The Company is pleased to announce that it has completed the US Food and Drug Administration (USFDA) inspection of Unit 4 at Visakhapatnam, Andhra Pradesh, without any observations and no form 483 issued.

A press release to this extent is also attached for your information and records.

Thanking you,

Yours sincerely,  
For Laurus Labs Limited

  
G. Venkateswar Reddy  
Company Secretary



Encl: a.a.

## **LAURUS LABS COMPLETES USFDA INSPECTION OF UNIT 4 WITHOUT ANY OBSERVATIONS**

Hyderabad, July 12, 2019, Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010)

Laurus Labs Ltd is pleased to announce that the maiden USFDA audit for its Unit 4 was successfully completed without any observations and no form 483 issued. The inspection was carried out from 8th July 2019 – 12 July 2019.

### **About Laurus Labs Limited**

Laurus Labs is a leading research & development driven and fully integrated pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APIs in Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. The company has also ventured into develop a Finished Dosages Forms on the back of existing strengths in APIs with a current capacity of 5 billion units per year, expandable up to 8 billion units per year. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses.

**Corporate Identification No: L24239AP2005PLC047518**

For more information about us, please visit <http://www.lauruslabs.com> or Contact particulars:

**Pavan Kumar N**  
**Laurus Labs Ltd.**  
**Tel: +91 40 3980 4380**  
**Email: [mediarelations@lauruslabs.com](mailto:mediarelations@lauruslabs.com)**



**DISCLAIMER:** Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.